196 related articles for article (PubMed ID: 27783363)
41. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
[TBL] [Abstract][Full Text] [Related]
42. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
Aue G; Lindorfer MA; Beum PV; Pawluczkowycz AW; Vire B; Hughes T; Taylor RP; Wiestner A
Haematologica; 2010 Feb; 95(2):329-32. PubMed ID: 19679883
[TBL] [Abstract][Full Text] [Related]
43. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
44. The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
Scialdone A; Hasni MS; Damm JK; Lennartsson A; Gullberg U; Drott K
Oncotarget; 2017 Jun; 8(23):37409-37422. PubMed ID: 28445158
[TBL] [Abstract][Full Text] [Related]
45. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
[TBL] [Abstract][Full Text] [Related]
46. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
[TBL] [Abstract][Full Text] [Related]
47. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
[TBL] [Abstract][Full Text] [Related]
48. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
49. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Manshouri T; Do KA; Wang X; Giles FJ; O'Brien SM; Saffer H; Thomas D; Jilani I; Kantarjian HM; Keating MJ; Albitar M
Blood; 2003 Apr; 101(7):2507-13. PubMed ID: 12446458
[TBL] [Abstract][Full Text] [Related]
50. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
[TBL] [Abstract][Full Text] [Related]
51. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
[TBL] [Abstract][Full Text] [Related]
52. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
53. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
Huh YO; Keating MJ; Saffer HL; Jilani I; Lerner S; Albitar M
Am J Clin Pathol; 2001 Sep; 116(3):437-43. PubMed ID: 11554173
[TBL] [Abstract][Full Text] [Related]
54. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
55. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
56. Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.
Watanabe N; Takahashi T; Sugimoto N; Tanaka Y; Kurata M; Matsushita A; Maeda A; Nagai K; Nasu K
Int J Clin Oncol; 2005 Oct; 10(5):357-61. PubMed ID: 16247665
[TBL] [Abstract][Full Text] [Related]
57. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
[TBL] [Abstract][Full Text] [Related]
58. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
Tam CS; Otero-Palacios J; Abruzzo LV; Jorgensen JL; Ferrajoli A; Wierda WG; Lerner S; O'Brien S; Keating MJ
Br J Haematol; 2008 Apr; 141(1):36-40. PubMed ID: 18324964
[TBL] [Abstract][Full Text] [Related]
59. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
Farag SS; Flinn IW; Modali R; Lehman TA; Young D; Byrd JC
Blood; 2004 Feb; 103(4):1472-4. PubMed ID: 14563637
[TBL] [Abstract][Full Text] [Related]
60. miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Gagez AL; Duroux-Richard I; Leprêtre S; Orsini-Piocelle F; Letestu R; De Guibert S; Tuaillon E; Leblond V; Khalifa O; Gouilleux-Gruart V; Banos A; Tournilhac O; Dupuis J; Jorgensen C; Cartron G; Apparailly F
Haematologica; 2017 Apr; 102(4):746-754. PubMed ID: 28126961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
